You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.
A US Senate panel is considering legislation that would expand the array of subject matter that is eligible to be patented.
A draft bill provides for a major expansion of eligible material, a move the ACLU and AMP said threatens to reduce competition in genetic testing.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
A new analysis finds that one company filed most of the patents on genes from deep-sea organisms, the Independent reports.
A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.
In February, the USPTO's Patent Trial and Appeal Board stopped UC's bid for IP underpinning the most lucrative applications of genome editing.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.